| “Pure” hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms P Mattiolo, A Mafficini, RT Lawlor, G Marchegiani, G Malleo, A Pea, ... Virchows Archiv 481 (1), 41-47, 2022 | 9 | 2022 |
| 1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma M Reni, F Bergamo, E Giommoni, M Milella, L Cavanna, MC Di Marco, ... Annals of Oncology 31, S953, 2020 | | 2020 |
| 1664P Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal … M Reni, E Giommoni, F Bergamo, L Cavanna, TP Latiano, M Spada, ... Annals of Oncology 34, S915-S916, 2023 | | 2023 |
| 2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy C Fontanella, V Fanotto, M Uccello, E Vasile, S Bozzarelli, R Filippi, ... European Journal of Cancer 3 (51), S454-S455, 2015 | | 2015 |
| 40 ThinPrepR CYTOLOGICAL SPECIMENS ARE OFTEN MORE SUITABLE THAN HISTOLOGICAL SPECIMENS TO DETECT EGFR AND K-RAS MUTATIONS IN NSCLC AND COLORECTAL CARCINOMA D Galetta, G Simone, D Petriella, V Rubini, R Pinto, R Daprile, A Paradiso, ... Cancer Treatment Reviews, S106-S107, 2010 | | 2010 |
| 5 PANITUMUMAB PLUS CHEMOTHERAPY AS SALVAGE TREATMENT IN PRETREATED ADVANCED COLORECTAL CANCER PATIENTS: A SINGLE INSTITUTION'S EXPERIENCE F Giuliani, P Cito, M Porcelli, A Misino, A Latorre, N Silvestris, M Guida, ... Cancer Treatment Reviews, S96, 2010 | | 2010 |
| 65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts G Rovesti, F Leone, G Brandi, S Cesario, M Scartozzi, M Niger, C Yoo, ... Annals of Oncology 31, S266, 2020 | | 2020 |
| A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium MV Lenti, DG Ribaldone, FB de Andreis, M Vernero, B Barberio, ... ESMO open 9 (7), 103632, 2024 | | 2024 |
| A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against … N Silvestris, G Apolone, G Botti, G Ciliberto, M Costantini, P De Paoli, ... Journal of Experimental & Clinical Cancer Research 39, 1-4, 2020 | 10 | 2020 |
| A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI … R Labianca, G Rosati, N Fazio, L Cavanna, D Ferrari, M Di Bartolomeo, ... Annals of Oncology 30, v312-v313, 2019 | | 2019 |
| A novel prognostic tool in western and eastern biliary tract cancer patients treated in first-line setting: the ECSIPOT index G Rovesti, F Leone, G Brandi, S Cesario, M Scartozzi, M Niger, C Yoo, ... Journal of Gastrointestinal Cancer 53 (3), 528-536, 2022 | 1 | 2022 |
| A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer V Lorusso, E Crucitta, N Silvestris, M Guida, A Misino, A Latorre, ... Clinical Breast Cancer 4 (2), 138-141, 2003 | 32 | 2003 |
| A phase I study of vinorelbine plus capecitabine in patients with advanced breast cancer D Sambiasi, A Misino, N Silvestris Ann Oncol 13 (Suppl 5), 56, 2002 | 6 | 2002 |
| A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy R Filippi, F Montagnani, P Lombardi, L Fornaro, G Aprile, ... Acta Oncologica 60 (10), 1317-1324, 2021 | 5 | 2021 |
| A promising role of TGF-β pathway in response to regorafenib in metastatic colorectal cancer: a case report S De Summa, K Danza, B Pilato, G Matera, R Fasano, A Calabrese, ... Medicina 57 (11), 1241, 2021 | 4 | 2021 |
| A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced … G Rosati, CA Cella, L Cavanna, C Codeca, M Prisciandaro, S Mosconi, ... Gastric Cancer 25 (4), 783-793, 2022 | 2 | 2022 |
| A roadmap to immunotherapy: lesson from the hallmarks and signaling pathways of cancer A Derakhshani, Z Rostami, H Safarpour, S Taefehshokr, NJ Tabrizi, ... Preprints, 2020 | | 2020 |
| A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery MA Shadbad, Z Asadzadeh, A Derakhshani, N Hosseinkhani, ... Biomedicine & Pharmacotherapy 143, 112213, 2021 | 22 | 2021 |
| A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: a single-cell RNA sequencing-based study MA Shadbad, F Ghorbaninezhad, H Hassanian, NK Ahangar, ... Frontiers in Medicine 9, 1027758, 2022 | 8 | 2022 |
| A systematic review and meta-analysis on the significance of TIGIT in solid cancers: Dual TIGIT/PD-1 blockade to overcome immune-resistance in solid cancers N Hosseinkhani, MA Shadbad, M Asghari Jafarabadi, N Karim Ahangar, ... International Journal of Molecular Sciences 22 (19), 10389, 2021 | 17 | 2021 |
daniele santiniprofessor in general pathology在 unicampus.it 的电子邮件经过验证
